Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.

Barzi A, Lara PN Jr, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S.

Cancer. 2019 Nov 1;125(21):3853-3863. doi: 10.1002/cncr.32290. Epub 2019 Aug 9.

PMID:
31398279
2.

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC).

Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME.

Clin Genitourin Cancer. 2019 Aug;17(4):241-247.e1. doi: 10.1016/j.clgc.2019.02.010. Epub 2019 Mar 19.

PMID:
31227432
3.

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.

Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, Jaimes Y, Tyagi R, Gonzales R, Grino M, Pinski JK, Barzi A, Raez LE, Eberhardt WE, Theegarten D, Lenz HJ, Uetake H, Danenberg PV, Danenberg K.

Biochem Biophys Res Commun. 2018 Jun 7;500(3):621-625. doi: 10.1016/j.bbrc.2018.04.120. Epub 2018 Apr 30.

PMID:
29679564
4.

Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.

Shahabi A, Lewinger JP, Ren J, April C, Sherrod AE, Hacia JG, Daneshmand S, Gill I, Pinski JK, Fan JB, Stern MC.

Prostate. 2016 Oct;76(14):1239-56. doi: 10.1002/pros.23211. Epub 2016 Jun 8.

PMID:
27272349
5.

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

Shahabi A, Satkunasivam R, Gill IS, Lieskovsky G, Daneshmand S, Pinski JK, Stern MC.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E17-22. doi: 10.5489/cuaj.3163. Epub 2016 Jan 14.

6.

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK.

Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489. Epub 2014 Oct 2.

7.

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.

Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):359-65. doi: 10.1038/pcan.2014.37. Epub 2014 Sep 23.

8.

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases.

Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB.

Urology. 2014 Jan;83(1):159-65. doi: 10.1016/j.urology.2013.08.074. Epub 2013 Nov 12. Erratum in: Urology. 2014 Jun;83(6):1446.

PMID:
24238569
9.

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK.

Clin Genitourin Cancer. 2013 Dec;11(4):416-22. doi: 10.1016/j.clgc.2013.07.011. Epub 2013 Oct 4.

PMID:
24099865
10.

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI.

J Nucl Med. 2013 Aug;54(8):1195-201. doi: 10.2967/jnumed.112.114116. Epub 2013 Jun 19.

11.

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI.

Clin Nucl Med. 2012 Jul;37(7):637-43. doi: 10.1097/RLU.0b013e318252d829.

12.

Immune response to sipuleucel-T in prostate cancer.

Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI.

Cancers (Basel). 2012 Apr 18;4(2):420-41. doi: 10.3390/cancers4020420.

13.

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.

Thara E, Dorff TB, Pinski JK, Quinn DI.

Maturitas. 2011 Aug;69(4):296-303. doi: 10.1016/j.maturitas.2011.04.012. Epub 2011 May 31. Review.

PMID:
21621934
14.

The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.

Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK.

Prostate. 2010 Nov 1;70(15):1692-700. doi: 10.1002/pros.21204.

PMID:
20564320
15.

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer.

Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN Jr, Van Veldhuizen PJ Jr, Quinn DI, Vogelzang NJ, Thompson IM Jr, Hussain MH.

Clin Cancer Res. 2010 Jun 1;16(11):3028-34. doi: 10.1158/1078-0432.CCR-09-3122. Epub 2010 May 18.

16.

Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells.

Mori R, Xiong S, Wang Q, Tarabolous C, Shimada H, Panteris E, Danenberg KD, Danenberg PV, Pinski JK.

Prostate. 2009 Jan 1;69(1):12-23. doi: 10.1002/pros.20851.

PMID:
18814146
17.

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.

Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW.

BJU Int. 2008 Dec;102(11):1601-6. doi: 10.1111/j.1464-410X.2008.08017.x. Epub 2008 Sep 8.

18.

Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer.

Mori R, Wang Q, Danenberg KD, Pinski JK, Danenberg PV.

Prostate. 2008 Oct 1;68(14):1555-60. doi: 10.1002/pros.20815.

PMID:
18651557
19.

Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.

Mori R, Wang Q, Quek ML, Tarabolous C, Cheung E, Ye W, Groshen S, Hawes D, Togo S, Shimada H, Danenberg KD, Danenberg PV, Pinski JK.

Anticancer Res. 2008 Jan-Feb;28(1B):425-30.

20.

Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.

Jia L, Shen HC, Wantroba M, Khalid O, Liang G, Wang Q, Gentzschein E, Pinski JK, Stanczyk FZ, Jones PA, Coetzee GA.

Mol Cell Biol. 2006 Oct;26(19):7331-41.

21.

EphB4 expression and biological significance in prostate cancer.

Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS.

Cancer Res. 2005 Jun 1;65(11):4623-32.

22.

Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.

Jadvar H, Kherbache HM, Pinski JK, Conti PS.

Clin Nephrol. 2003 Dec;60(6):395-400.

PMID:
14690256
23.

FDG PET in suspected recurrent and metastatic prostate cancer.

Jadvar H, Pinski JK, Conti PS.

Oncol Rep. 2003 Sep-Oct;10(5):1485-8.

PMID:
12883728

Supplemental Content

Loading ...
Support Center